Evidence map›Paper›PMID 38597989›Full record

ArticleCellular and molecular life sciences : CMLS2024

The E3 ubiquitin ligase ITCH negatively regulates intercellular communication via gap junctions by targeting connexin43 for lysosomal degradation.

Max Zachrisson Totland, Lars Mørland Knudsen, Nikoline Lander Rasmussen, Yasufumi Omori, Vigdis Sørensen, Vilde C Wivestad Elster, Jakob Mørkved Stenersen, Mathias Larsen, Caroline Lunder Jensen, Anna A Zickfeldt Lade and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

Max Zachrisson Totland *Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Lars Mørland Knudsen *Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Nikoline Lander RasmussenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Yasufumi OmoriDepartment of Molecular and Tumour Pathology, Akita University Graduate School of Medicine, Akita, 010-8543, Japan.
Vigdis SørensenDepartment of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Vilde C Wivestad ElsterDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Jakob Mørkved StenersenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Mathias LarsenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Caroline Lunder JensenDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Anna A Zickfeldt LadeDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Emilie BruusgaardDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Sebastian BasingDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Kushtrim KryeziuDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Andreas BrechDepartment of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Trond AasenPatologia Molecular Translacional, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain.
Ragnhild A LotheDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.
Edward LeitheDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, NO-0424, Norway.ORCID http://orcid.org/0000-0003-0831-2642
Oslo University Hospital · NOAkita University · JPVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intercellular communication via gap junctions has a fundamental role in regulating cell growth and tissue homeostasis, and its dysregulation may be involved in cancer development and radio- and chemotherapy resistance. Connexin43 (Cx43) is the most ubiquitously expressed gap junction channel protein in human tissues. Emerging evidence indicates that dysregulation of the sorting of Cx43 to lysosomes is important in mediating the loss of Cx43-based gap junctions in cancer cells. However, the molecular basis underlying this process is currently poorly understood. Here, we identified the E3 ubiquitin ligase ITCH as a novel regulator of intercellular communication via gap junctions. We demonstrate that ITCH promotes loss of gap junctions in cervical cancer cells, which is associated with increased degradation of Cx43 in lysosomes. The data further indicate that ITCH interacts with and regulates Cx43 ubiquitination and that the ITCH-induced loss of Cx43-based gap junctions requires its catalytic HECT (homologous to E6-AP C-terminus) domain. The data also suggest that the ability of ITCH to efficiently promote loss of Cx43-based gap junctions and degradation of Cx43 depends on a functional PY (PPXY) motif in the C-terminal tail of Cx43. Together, these data provide new insights into the molecular basis underlying the degradation of Cx43 and have implications for the understanding of how intercellular communication via gap junctions is lost during cancer development.

Indexed as

Connexin 43Ubiquitin-Protein LigasesCell CommunicationConnexinsGap JunctionsHumansLysosomesRepressor ProteinsConnexin 43ConnexinsGJA1 protein, humanITCH protein, humanRepressor ProteinsUbiquitin-Protein LigasesCervixConnexinDeubiquitinationEndosomeNEDD4

Identifiers

PMID38597989
PMCPMC11006747
OpenAlexW4394688913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.